# US 2020/0171109 A1 · Method for inducing production of vascular endothelial growth factor

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0171109 A1
- Document ID: US20200171109A1
- Status: Published application
- Kind: A1
- Application number: 16/783,717
- Filed: 2020-02-06
- Published: 2020-06-04
- Earliest claimed: 2009-08-31
- Inventors: Tadashi Tanabe; Keiichi Hukuda; Takashi Kawakami
- Web page: https://patentgrep.com/patent/US20200171109A1

## CPC

- A61K 35/76: Viruses; Subviral particles; Bacteriophages
- A61K 31/5585: having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin
- A61K 38/1825: {Fibroblast growth factor [FGF]}
- A61K 38/1833: {Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II}
- A61K 38/1866: {Vascular endothelial growth factor [VEGF]}
- A61K 38/52: Isomerases (5)
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 48/005: {characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered}
- A61P 7/02: Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/08: Vasodilators for multiple indications
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- C12Y 503/99004: Prostaglandin-I synthase (5.3.99.4)
- A61K 35/13: Tumour cells, irrespective of tissue of origin (tumour vaccines A61K39/00)
- C12N 2750/14132: Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- C12N 2750/14143: viral genome or elements thereof as genetic vector
- C12N 2799/025: where the vector is derived from a parvovirus
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Y: ENZYMES

## Abstract

The present invention relates to a method for inducing production of vascular endothelial growth factor (VEGF). The method includes administering, to an individual, a composition including adeno-associated virus (AAV) carrying a hPGIS gene coding for human prostacyclin synthase (hPGIS) which synthesizes prostaglandin I2 (PGI2).

## Claims

### Claim 1

A method for inducing production of vascular endothelial growth factor (VEGF), the method comprising: administering, to an individual, a composition comprising an adeno-associated virus (AAV) carrying a hPGIS gene coding for human prostacyclin synthase (hPGIS) and a second gene coding for an angiogenesis factor selected from the group consisting of genes coding for vascular endothelial growth factor (VEGF) and VEGF-2, wherein the hPGIS synthesizes prostaglandin I2 (PGI2) and induces production of VEGF in the individual.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the AAV is of a type selected from the group consisting of type 1, 2, 5 and 8.

### Claim 3 (depends on 1)

The method according to claim 1, wherein the AAV is of a type selected from the group consisting of type 1 and 2.

### Claim 4 (depends on 1)

The method according to claim 1, wherein the AAV induces one or more activities selected from the group containing of vasodilation, anti-platelet aggregation, and angiogenesis.

### Claim 5 (depends on 1)

The method according to claim 1, wherein the composition further comprises a pharmaceutically permissible carrier containing the AAV, the carrier being selected from the group consisting of water, a water-propylene glycol mixed solution, a buffered solution, and 0.4% saline.

### Claim 6 (depends on 1)

The method according to claim 1, wherein the second gene coding for an angiogenesis factor is a VEGF.

### Claim 7 (depends on 1)

The method according to claim 1, wherein the AAV induces one or more activities selected from the group containing of vasodilation, anti-platelet aggregation, and angiogenesis.

### Claim 8 (depends on 1)

The method according to claim 1, wherein the composition further comprises a pharmaceutically permissible carrier containing the AAV, the carrier being selected from the group consisting of water, a water-propylene glycol mixed solution, a buffered solution, and 0.4% saline.
